intelligence360
  • About us
  • Contact Us
  • Search Icon

intelligence360

The Intelligent News Source

VedaBio Announces Strategic Agreement with Siemens Healthineers and Series A Extension, Totaling Up to $25 Million

VedaBio Announces Strategic Agreement with Siemens Healthineers and Series A Extension, Totaling Up to $25 Million

September 30, 2025 Craig Etkin

SAN DIEGO–(BUSINESS WIRE)–VedaBio, a pioneering biotechnology company transforming molecular detection, today announced a Series A extension alongside a strategic agreement with Siemens Healthineers. Together, these commitments total up to $25 million for advancing VedaBio’s CRISPR-based product platform. Moreover, it is an important step in validating VedaBio’s vision of leveraging an amplification-free technology to meet critical unmet needs in decentralized molecular diagnostics.

“The combination of our investors’ support and the strategic agreement with Siemens Healthineers marks a pivotal moment for VedaBio,” said Frederic Sweeney, PhD, President and CEO of VedaBio.Share

“The combination of our investors’ support and the strategic agreement with Siemens Healthineers marks a pivotal moment for VedaBio,” said Frederic Sweeney, PhD, President and CEO of VedaBio. “We have assembled one of the most experienced and capable teams in molecular diagnostics which, together with our innovative platform, positions us to redefine how clinical diagnostics are delivered. This milestone not only strengthens our financial position but also aligns us with a world-class leader in the space.”

VedaBio’s amplification-free CRISPR-based approach provides an innovative solution to address significant gaps in patient care.

This announcement follows VedaBio’s recently disclosed partnership with Mammoth Biosciences, which expanded the company’s access to key CRISPR technologies. Together, these milestones underscore VedaBio’s momentum in building a next-generation molecular diagnostics platform as the company continues to advance its product development.

About VedaBio

VedaBio is at the forefront of molecular detection, harnessing cutting-edge CRISPR technology to deliver rapid, accurate, and accessible diagnostics. The company is dedicated to advancing the next generation of molecular diagnostics to improve healthcare outcomes worldwide.

For more information, visit vedabio.com.

Contacts

Media contact
Karen Sharma
CG Life
ksharma@cglife.com


Venture Capital
California, San Diego, VedaBio, Venture Capital

Post navigation

NEXT
Brand Advocacy Platform, Duel, Raises $16M in Series A
PREVIOUS
Pattern Announces Closing of Initial Public Offering
Comments are closed.

Categories

Recent Posts

  • Champions Series Pickleball has filed a notice of an exempt offering of securities to raise $5,600,000.00 in New Funding. August 25, 2026
  • Carnot Labs dba Reservoir has filed a notice of an exempt offering of securities to raise $4,951,003.00 in New Funding. August 25, 2026
  • CarePredict has filed a notice of an exempt offering of securities to raise $10 Million in New Funding. August 25, 2026
  • Blue Arbor Technologies has filed a notice of an exempt offering of securities to raise $10,174,987.00 in New Funding. August 25, 2026

Archives

© 2026   Copyright SI360 Inc. All Rights Reserved.